Evommune, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Evommune, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$13.00M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$81.07M
Operating income as a percentage of revenue.	-623.6%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$68.87M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-11.22
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-11.22

Balance Sheet

	2025-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$44.06M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$224.95M
Everything the company owes — debt, unpaid bills, and other obligations.	$19.38M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$205.57M

Cash Flow Statement

	2025-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$76.44M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$235000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$76.68M